JP2012525854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525854A5 JP2012525854A5 JP2012510026A JP2012510026A JP2012525854A5 JP 2012525854 A5 JP2012525854 A5 JP 2012525854A5 JP 2012510026 A JP2012510026 A JP 2012510026A JP 2012510026 A JP2012510026 A JP 2012510026A JP 2012525854 A5 JP2012525854 A5 JP 2012525854A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- polypeptide
- amino acid
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 141
- 108091033319 polynucleotide Proteins 0.000 claims description 99
- 102000040430 polynucleotide Human genes 0.000 claims description 99
- 239000002157 polynucleotide Substances 0.000 claims description 99
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 85
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 229920001184 polypeptide Polymers 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 102000039446 nucleic acids Human genes 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 47
- 150000007523 nucleic acids Chemical class 0.000 claims description 47
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 8
- 108700010070 Codon Usage Proteins 0.000 claims description 4
- 239000000203 mixture Substances 0.000 description 30
- 238000006467 substitution reaction Methods 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100034384 Plexin-B1 Human genes 0.000 description 3
- 101710100559 Plexin-B1 Proteins 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- -1 biotoxin Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17682609P | 2009-05-08 | 2009-05-08 | |
| US61/176,826 | 2009-05-08 | ||
| US32521310P | 2010-04-16 | 2010-04-16 | |
| US61/325,213 | 2010-04-16 | ||
| PCT/US2010/034116 WO2010129917A2 (en) | 2009-05-08 | 2010-05-07 | Anti-cd100 antibodies and methods for using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016013547A Division JP6096946B2 (ja) | 2009-05-08 | 2016-01-27 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525854A JP2012525854A (ja) | 2012-10-25 |
| JP2012525854A5 true JP2012525854A5 (https=) | 2015-05-28 |
| JP6059013B2 JP6059013B2 (ja) | 2017-01-11 |
Family
ID=43050912
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510026A Active JP6059013B2 (ja) | 2009-05-08 | 2010-05-07 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
| JP2016013547A Active JP6096946B2 (ja) | 2009-05-08 | 2016-01-27 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
| JP2017026605A Pending JP2017113017A (ja) | 2009-05-08 | 2017-02-16 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016013547A Active JP6096946B2 (ja) | 2009-05-08 | 2016-01-27 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
| JP2017026605A Pending JP2017113017A (ja) | 2009-05-08 | 2017-02-16 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US8496938B2 (https=) |
| EP (2) | EP2427212B1 (https=) |
| JP (3) | JP6059013B2 (https=) |
| KR (2) | KR20170080705A (https=) |
| CN (2) | CN108912228B (https=) |
| AU (2) | AU2010245668B2 (https=) |
| CA (1) | CA2760890C (https=) |
| DK (1) | DK2427212T3 (https=) |
| EA (1) | EA025245B1 (https=) |
| ES (1) | ES2647823T3 (https=) |
| IL (3) | IL216002A (https=) |
| MX (2) | MX2011011718A (https=) |
| NO (1) | NO2427212T3 (https=) |
| NZ (2) | NZ618067A (https=) |
| PL (1) | PL2427212T3 (https=) |
| PT (1) | PT2427212T (https=) |
| SG (1) | SG175417A1 (https=) |
| WO (1) | WO2010129917A2 (https=) |
| ZA (1) | ZA201108162B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010129917A2 (en) | 2009-05-08 | 2010-11-11 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| EP2487242A1 (en) * | 2011-02-09 | 2012-08-15 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
| MX343640B (es) | 2011-05-13 | 2016-11-15 | Nat Univ Corp Tokyo Medical & Dental Univ | Promotor de osteogenesis. |
| AU2012322721B2 (en) * | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) * | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| US10626163B2 (en) | 2013-01-25 | 2020-04-21 | Brandeis University | Methods of modulating GABAergic inhibitory synapse formation and function |
| SG10201708048XA (en) | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| US10577427B2 (en) | 2016-04-22 | 2020-03-03 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| BR112019001944A2 (pt) | 2016-08-02 | 2019-05-07 | Vaccinex, Inc. | métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia |
| AU2017335634A1 (en) | 2016-09-27 | 2019-03-14 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| ES2963046T3 (es) | 2017-03-20 | 2024-03-25 | Vaccinex Inc | Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético |
| SG11201908744PA (en) * | 2017-03-23 | 2019-10-30 | Univ Pennsylvania | Anti-c5a antibodies and uses thereof |
| CA3061963A1 (en) | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| EP4714966A2 (en) | 2017-09-26 | 2026-03-25 | Cero Therapeutics Holdings, Inc. | Chimeric engulfment receptor molecules and methods of use |
| MX2020010241A (es) | 2018-03-28 | 2020-10-16 | Cero Therapeutics Inc | Composiciones de inmunoterapia celular y usos de las mismas. |
| WO2019191332A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| CN109125731B (zh) * | 2018-10-22 | 2019-10-25 | 华中科技大学同济医学院附属协和医院 | Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用 |
| WO2020198572A1 (en) | 2019-03-28 | 2020-10-01 | Vaccinex, Inc. | Semaphorin-4d antagonists for use in cancer therapy |
| IL288779B2 (en) | 2019-06-21 | 2025-11-01 | Vaccinex Inc | Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy |
| CN114341170B (zh) * | 2019-07-19 | 2023-09-01 | 神州细胞工程有限公司 | 一种人源化抗vegfr2抗体及其应用 |
| AU2020322474A1 (en) * | 2019-08-01 | 2022-03-10 | Vaccinex,Inc. | Combined inhibition of semaphorin-4D and TGFβ and compositions therefor |
| CN117597360A (zh) | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| CN113583122B (zh) * | 2021-07-29 | 2023-08-29 | 武汉华美生物工程有限公司 | 抗人sema4d抗体及其制备方法和应用 |
| JP2024535403A (ja) | 2021-09-27 | 2024-09-30 | バクシネックス インコーポレーティッド | 神経変性障害を処置するための抗セマフォリン４ｄ結合分子の使用に関する予測アウトカムプロファイリング |
| WO2023081766A2 (en) * | 2021-11-03 | 2023-05-11 | Rutgers, The State University Of New Jersey | Antibody-drug conjugates against the receptor tyrosine kinase epha5 |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| CN117866091A (zh) * | 2022-10-12 | 2024-04-12 | 三优生物医药(上海)有限公司 | 抗cd100抗体及其用途 |
| CN118108841A (zh) * | 2022-11-30 | 2024-05-31 | 三优生物医药(上海)有限公司 | 抗cd100抗体及其用途 |
| WO2026030311A1 (en) | 2024-07-29 | 2026-02-05 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules to treat cognitive impairment |
| WO2026080818A1 (en) | 2024-10-10 | 2026-04-16 | Vaccinex, Inc. | Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5070192A (en) * | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| CA2153165C (en) * | 1993-01-14 | 2003-05-06 | Hiroaki Maeda | Recombinant anti-hiv antibody and process for preparing the same |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| CA2286477A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| ATE407206T1 (de) | 1998-11-10 | 2008-09-15 | Univ Rochester | Methoden zu herstellung von genbanken |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| US7468277B2 (en) | 1999-12-23 | 2008-12-23 | Cornell Research Foundation, Inc. | Enriched preparation of human fetal multipotential neural stem cells |
| CN1329060A (zh) * | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸 |
| AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| CA2450793A1 (en) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20030020733A1 (en) | 2001-07-24 | 2003-01-30 | Yin Memphis Zhihong | Computer display having selective area magnification |
| ITTO20010128U1 (it) | 2001-07-25 | 2003-01-25 | Aris Spa | Struttura ausiliaria particolarmente per l'incremento della capacita'di trasporto dei veicoli cingolati polivalenti tipo m 113 e derivati. |
| US6905856B2 (en) * | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20080219974A1 (en) * | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| ATE483472T1 (de) * | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| UA101945C2 (uk) | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лікування злоякісного новоутворення за допомогою бевацизумабу |
| AU2004272607B2 (en) * | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| AU2004296184B2 (en) | 2003-12-04 | 2010-12-16 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| CA2575402A1 (en) | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| US7919246B2 (en) * | 2005-04-07 | 2011-04-05 | Novartis Vaccines And Diagnostics, Inc. | SEMA4D in cancer diagnosis, detection and treatment |
| BRPI0618609A2 (pt) * | 2005-11-16 | 2011-09-06 | Novartis Ag | biomarcadores para tratamento com anticorpo anti-nogo-a em danos à medula espinhal |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US7657639B2 (en) * | 2006-07-21 | 2010-02-02 | International Business Machines Corporation | Method and system for identity provider migration using federated single-sign-on operation |
| US8257706B2 (en) * | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| US7919594B2 (en) * | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| AU2008219020B2 (en) | 2007-02-21 | 2013-08-22 | Vaccinex, Inc. | Modulation of NKT cell activity with antigen-loaded CDId molecules |
| CA2710680C (en) | 2007-12-26 | 2018-10-16 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
| AR070134A1 (es) | 2008-01-10 | 2010-03-17 | Genentech Inc | Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso |
| WO2010129917A2 (en) | 2009-05-08 | 2010-11-11 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| NZ605260A (en) | 2010-06-14 | 2013-12-20 | Joseph King Allan | Anti-vegf antibodies and uses thereof |
| SG188285A1 (en) | 2010-09-02 | 2013-04-30 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
| MX343640B (es) | 2011-05-13 | 2016-11-15 | Nat Univ Corp Tokyo Medical & Dental Univ | Promotor de osteogenesis. |
| RU2014117952A (ru) | 2011-10-06 | 2015-11-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела против sema4a человека, используемые для лечения заболевания |
| AU2012322721B2 (en) | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| NZ629828A (en) | 2012-03-02 | 2017-05-26 | Vaccinex Inc | Methods for the treatment of b cell-mediated inflammatory diseases |
| US9375282B2 (en) | 2012-03-26 | 2016-06-28 | Covidien Lp | Light energy sealing, cutting and sensing surgical device |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| CN105408355A (zh) | 2013-01-31 | 2016-03-16 | 瓦克纳斯有限公司 | 用于提高免疫球蛋白a水平的方法 |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| US10577427B2 (en) | 2016-04-22 | 2020-03-03 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| BR112019001944A2 (pt) | 2016-08-02 | 2019-05-07 | Vaccinex, Inc. | métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia |
| EP3585435A4 (en) | 2017-02-22 | 2020-12-16 | Vaccinex, Inc. | EARLY DETECTION OF GLIAL CELL ACTIVATION IN NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISEASES |
-
2010
- 2010-05-07 WO PCT/US2010/034116 patent/WO2010129917A2/en not_active Ceased
- 2010-05-07 US US12/776,187 patent/US8496938B2/en active Active
- 2010-05-07 EP EP10772913.9A patent/EP2427212B1/en active Active
- 2010-05-07 PT PT107729139T patent/PT2427212T/pt unknown
- 2010-05-07 MX MX2011011718A patent/MX2011011718A/es active IP Right Grant
- 2010-05-07 DK DK10772913.9T patent/DK2427212T3/en active
- 2010-05-07 JP JP2012510026A patent/JP6059013B2/ja active Active
- 2010-05-07 CN CN201810367413.1A patent/CN108912228B/zh active Active
- 2010-05-07 AU AU2010245668A patent/AU2010245668B2/en active Active
- 2010-05-07 NO NO10772913A patent/NO2427212T3/no unknown
- 2010-05-07 KR KR1020177017649A patent/KR20170080705A/ko not_active Ceased
- 2010-05-07 MX MX2014010424A patent/MX353352B/es unknown
- 2010-05-07 KR KR1020117029324A patent/KR101754433B1/ko active Active
- 2010-05-07 NZ NZ618067A patent/NZ618067A/en unknown
- 2010-05-07 SG SG2011080025A patent/SG175417A1/en unknown
- 2010-05-07 CN CN201080029914.0A patent/CN102458468B/zh active Active
- 2010-05-07 EA EA201171374A patent/EA025245B1/ru unknown
- 2010-05-07 EP EP17186852.4A patent/EP3320920A1/en not_active Withdrawn
- 2010-05-07 ES ES10772913.9T patent/ES2647823T3/es active Active
- 2010-05-07 NZ NZ596136A patent/NZ596136A/en active IP Right Revival
- 2010-05-07 PL PL10772913T patent/PL2427212T3/pl unknown
- 2010-05-07 CA CA2760890A patent/CA2760890C/en active Active
-
2011
- 2011-10-27 IL IL216002A patent/IL216002A/en active IP Right Grant
- 2011-11-07 ZA ZA2011/08162A patent/ZA201108162B/en unknown
-
2012
- 2012-06-14 US US13/517,807 patent/US8816058B2/en active Active
-
2013
- 2013-03-12 US US13/797,048 patent/US9605055B2/en active Active
- 2013-03-13 US US13/800,713 patent/US9676840B2/en active Active
-
2016
- 2016-01-27 JP JP2016013547A patent/JP6096946B2/ja active Active
- 2016-02-21 IL IL244197A patent/IL244197A0/en active IP Right Grant
- 2016-10-18 AU AU2016247068A patent/AU2016247068A1/en not_active Abandoned
-
2017
- 2017-02-16 JP JP2017026605A patent/JP2017113017A/ja active Pending
- 2017-04-28 US US15/581,573 patent/US11274149B2/en active Active
-
2018
- 2018-08-23 IL IL261348A patent/IL261348A/en unknown
-
2022
- 2022-01-31 US US17/588,427 patent/US12006364B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525854A5 (https=) | ||
| KR102257154B1 (ko) | Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법 | |
| US10766958B2 (en) | Methods of treating vitiligo using PD-1 binding antibodies | |
| JP2018533973A (ja) | Ｐｄ−１結合タンパク質及びその使用方法 | |
| RU2012137515A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| SG183872A1 (en) | Therapeutic dll4 binding proteins | |
| JP7350740B2 (ja) | Ｉｌｄｒ２アンタゴニストおよびその組み合わせ | |
| US20230416394A1 (en) | Novel conjugate molecules targeting cd39 and tgfbeta | |
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| JP7717687B2 (ja) | 腎疾患における抗幹細胞因子抗体及びその使用方法 | |
| KR20230132544A (ko) | 신규한 항-그렘린1 항체 | |
| KR20260008083A (ko) | Cd19/cd38 다중특이적 항체 | |
| KR20250152073A (ko) | 항체, 항원 결합 단편 및 사용 방법 | |
| US20250326852A1 (en) | Materials and methods for targeting regulatory t cells for enhancing immune surveillance | |
| CN119462927B (zh) | 靶向PD-L1和TGF-β的双功能分子 | |
| CN116940595A (zh) | 抗tigit抗体及其用途 | |
| KR20250133913A (ko) | TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도 | |
| JP2025516434A (ja) | 抗ｃｄ７３抗体およびその使用 | |
| HK40112825A (zh) | 抗干细胞因子抗体及其使用方法 | |
| CN118871465A (zh) | 针对btla的抗体及其用途 |